4.7 Article

A TLR2 ligand suppresses inflammation by modulation of chemokine receptors and redirection of leukocyte migration

Journal

BLOOD
Volume 113, Issue 18, Pages 4224-4231

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-08-174698

Keywords

-

Categories

Funding

  1. Medical Research Council (London, United Kingdom)
  2. The European Union INNOCHEM program
  3. Novartis Institutes for Biomedical Research ( Vienna, Austria)
  4. Cancer Research UK ( London, United Kingdom)
  5. TENOVUS Scotland ( Glasgow, United Kingdom).
  6. MRC [G0801198, G0700120] Funding Source: UKRI
  7. Medical Research Council [G0700120, G0801198] Funding Source: researchfish

Ask authors/readers for more resources

Toll-like receptors orchestrate rapid local protective innate-immune responses to invading pathogens and optimize leukocyte priming of subsequent adaptive responses. Paradoxically, systemic excess of the TLR2 ligand, bacterial lipoprotein (BLP), suppresses peripheral inflammatory responses. Here, we demonstrate that this phenomenon is regulated via the TLR2-dependent, cell-autonomous down-regulation of inflammatory chemokine receptor expression on a variety of leukocyte subsets. Remarkably, BLP mediated no effect on constitutive chemokine receptor expression. By tracking adoptively transferred wild-type and TLR2(-/-) leukocytes in vivo, we observed that BLP mediated chemokine receptor switching directed leukocytes away from inflamed sites toward secondary lymphoid organs. These data highlight a novel role for TLR ligands, such as BLP, in regulating leukocyte retention and migration away from innate immune lesions via discrete constitutive and inflammatory chemokine receptor regulation. ( Blood. 2009;113:4224-4231)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available